Fintel reports that on October 25, 2024, TD Cowen downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from ...

Fintel reports that on October 25, 2024, Jefferies downgraded their outlook for Marinus Pharmaceuticals (NasdaqGM:MRNS) from ...

On Thursday, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stock plunged after the company revealed disappointing data from the ...

Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an ...

H.C. Wainwright downgraded Marinus Pharmaceuticals (MRNS) to Neutral from Buy with a price target of $2, down from $11. The firm is ...

Marinus Pharmaceuticals (MRNS) stock was downgraded at TD Cowen and Truist after a Phase 3 failure for lead asset, ganaxolone ...

Marinus Pharmaceuticals has reported that the Phase III TrustTSC trial of oral ganaxolone in treating seizures linked to ...

The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...

The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Marinus Pharmaceuticals shares plunged nearly 80% to a new all-time low on Thursday after the pharmaceutical company said it is cutting jobs and exploring strategic options following the failure of ...

Marinus said it will discontinue development of the drug, ganaxolone, and take further steps to reduce costs, including job ...

On Friday, Marinus Pharmaceuticals Inc (MRNS) stock saw a modest uptick, ending the day at $1.85 which represents a slight increase of $0.11 or 6.32% from the prior close of $1.74. The stock opened at ...